Source of evidence: Financial Express: Beximco Pharma draws Myanmar mkt expansion plan 3/15/2006 Taking advantage of the exemptions of 'pharmaceutical product patent' for the least developed countries (LDCs) until 2016, as given by the Doha Declaration of Trade Related aspects of Intellectual Property rights (TRIPs), Beximco Pharmaceuticals participated in a three-day 'Pharmaceutical Product Show' in Myanmar with a massive market expansion plan, reports BDNEWS. All the TRIPs signatory countries excepting the 50 LDCs have already implemented 'pharmaceutical product patent' in their respective countries, paving the way for pharmaceutical companies in the LDCs to reap the benefit of Doha Declaration by exporting medicines in huge volumes to the LDCs including Myanmar, a 90 per cent import dependent LDC in the South East Asia. Beximco Pharma Chief Executive Officer Nazmul Hassan said the WTO rules have opened the prospects of good business in foreign market by big local companies like......
Join Now or Login to view the rest of this paper.
Approximate Word Count: 298
Approximate Pages: 2 (260 words per double-spaced page) |